Publication:
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

dc.contributor.coauthorOzyurt, Neslihan
dc.contributor.coauthorAlkan, Ali
dc.contributor.coauthorGulbagci, Burcu
dc.contributor.coauthorSeyyar, Mustafa
dc.contributor.coauthorAydin, Esra
dc.contributor.coauthorSahbazlar, Mustafa
dc.contributor.coauthorTurker, Mehmet
dc.contributor.coauthorKinikoglu, Oguzcan
dc.contributor.coauthorYerlikaya, Tahir
dc.contributor.coauthorDinc, Gulhan
dc.contributor.coauthorAytac, Ali
dc.contributor.coauthorKalkan, Ziya
dc.contributor.coauthorEbinc, Senar
dc.contributor.coauthorGulturk, Ilkay
dc.contributor.coauthorKeskinkilic, Merve
dc.contributor.coauthorIsleyen, Zehra Sucuoglu
dc.contributor.coauthorCaglayan, Dilek
dc.contributor.coauthorTurkel, Alper
dc.contributor.coauthorAydin, Esra
dc.contributor.coauthorSakalar, Teoman
dc.contributor.coauthorSekmek, Serhat
dc.contributor.coauthorYildirim, Nilgun
dc.contributor.coauthorKocak, Sinem
dc.contributor.coauthorOkutur, Kerem
dc.contributor.coauthorOzveren, Ahmet
dc.contributor.coauthorDursun, Bengu
dc.contributor.coauthorKitapli, Sait
dc.contributor.coauthorEren, Orhan Onder
dc.contributor.coauthorBeypinar, Ismail
dc.contributor.coauthorHacibekiroglu, Ilhan
dc.contributor.coauthorCabuk, Devrim
dc.contributor.coauthorKaraman, Elanur
dc.contributor.coauthorAcar, Omer
dc.contributor.coauthorPaydas, Semra
dc.contributor.coauthorEryilmaz, Melek Karakurt
dc.contributor.coauthorDemir, Bilgin
dc.contributor.coauthorOruc, Zeynep
dc.contributor.coauthorYilmaz, Mesut
dc.contributor.coauthorBiricik, Fatih Selcuk
dc.contributor.coauthorSalim, Derya Kivrak
dc.contributor.coauthorTanriverdi, Ozgur
dc.contributor.coauthorDogan, Mutlu
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorSelçukbiricik, Fatih
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-03-06T21:00:27Z
dc.date.issued2024
dc.description.abstractThe studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients who were treated with neoadjuvant chemotherapy (NAC) and surgery were analyzed retrospectively. The primary aim of the study was to analyze the impact of Her2 status(Her2-0 and Her2-low) on pathological complete response (pCR). The secondary objectives were disease free survival (DFS) and overall survival (OS). 620 female triple negative breast cancer patients were evaluated. 427 patients (68.9%) had Her2-0 and 193(31.1%) had her2-low pathology. The pCR rates were similar between Her2-0 and Her2-low patients (33.0% vs. 27.5%, p = 0.098). Although Her2-0 group has better DFS (106 vs. 50 months, p = 0.002), in multivariate analysis it had a HR of 0.74 (p = 0.06). In addition, OS was similar (131 vs. 105 months, p = 0.13) with a HR of 0.88 (p = 0.61). In multivariate analysis;presence of LVI (HR:2.2 (95% CI 1.1-3.5) p = 0.001), Clinical stage T1/T2 (HR:0.39 (95% CI 0.2-0.6) p < 0.001) and lymph node negativity (HR:0.35 (95% CI 0.1-0.9) p = 0.03) were independent factors for OS. Although there were pathological and clinical differences, the pCR, DFS and OS were similar between Her2-0 and Her2-low TNBC patients. The importance of Her2 status of TNBC in neoadjuvant setting should be further studied.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1038/s41598-024-75293-5
dc.identifier.issn2045-2322
dc.identifier.issue1
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85205955076
dc.identifier.urihttps://doi.org/10.1038/s41598-024-75293-5
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27893
dc.identifier.volume14
dc.identifier.wos1336389100004
dc.keywordsHer2 status
dc.keywordsTriple-negative breast cancer
dc.keywordsPrognosis
dc.keywordsTurkish Oncology Group
dc.keywordsBreast cancer subtypes
dc.keywordsOncology
dc.keywordsBiomarkers
dc.keywordsSurvival analysis
dc.keywordsClinical outcomes
dc.keywordsCancer research
dc.language.isoeng
dc.publisherNature Portfolio
dc.relation.ispartofScientific Reports
dc.subjectMultidisciplinary sciences
dc.titleThe prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorSelçukbiricik, Fatih
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files